These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36856671)

  • 1. A mini review for lipid-based nanovaccines: from their design to their applications.
    Xekouki K; Lagopati N; Demetzos C; Gazouli M; Pippa N
    J Liposome Res; 2023 Sep; 33(3):214-233. PubMed ID: 36856671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomes as vaccine delivery systems: a review of the recent advances.
    Schwendener RA
    Ther Adv Vaccines; 2014 Nov; 2(6):159-82. PubMed ID: 25364509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials.
    Vijayan V; Mohapatra A; Uthaman S; Park IK
    Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31615112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection.
    Xu F; Yuan Y; Wang Y; Yin Q
    Biomed Pharmacother; 2023 Feb; 158():114117. PubMed ID: 36528914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancements in prophylactic and therapeutic nanovaccines.
    Bhardwaj P; Bhatia E; Sharma S; Ahamad N; Banerjee R
    Acta Biomater; 2020 May; 108():1-21. PubMed ID: 32268235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-adjuvanting cancer nanovaccines.
    Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
    J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.
    Watson DS; Endsley AN; Huang L
    Vaccine; 2012 Mar; 30(13):2256-72. PubMed ID: 22306376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of vaccine formulations: past, present, and future.
    D'Amico C; Fontana F; Cheng R; Santos HA
    Drug Deliv Transl Res; 2021 Apr; 11(2):353-372. PubMed ID: 33598818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanovaccine: an emerging strategy.
    Das A; Ali N
    Expert Rev Vaccines; 2021 Oct; 20(10):1273-1290. PubMed ID: 34550859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colloidal drug delivery systems in vaccine delivery.
    Beg S; Samad A; Nazish I; Sultana R; Rahman M; Ahmad MZ; Akbar M
    Curr Drug Targets; 2013 Jan; 14(1):123-37. PubMed ID: 23072326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging advances in cationic liposomal cancer nanovaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Alasmary MY; Abdel-Wahab BA; Warsi MH; Haque A; Chaubey P
    Immunotherapy; 2021 Apr; 13(6):491-507. PubMed ID: 33626936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal adjuvants for human vaccines.
    Alving CR; Beck Z; Matyas GR; Rao M
    Expert Opin Drug Deliv; 2016 Jun; 13(6):807-16. PubMed ID: 26866300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticles and Vaccine Development.
    Kheirollahpour M; Mehrabi M; Dounighi NM; Mohammadi M; Masoudi A
    Pharm Nanotechnol; 2020; 8(1):6-21. PubMed ID: 31647394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approach.
    Soema PC; Willems GJ; Jiskoot W; Amorij JP; Kersten GF
    Eur J Pharm Biopharm; 2015 Aug; 94():427-35. PubMed ID: 26144666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.
    Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():615240. PubMed ID: 33679703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.
    De Serrano LO; Burkhart DJ
    J Nanobiotechnology; 2017 Nov; 15(1):83. PubMed ID: 29149896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanovaccines and their mode of action.
    Zaman M; Good MF; Toth I
    Methods; 2013 May; 60(3):226-31. PubMed ID: 23623821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymph node-targeting nanovaccines for cancer immunotherapy.
    Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
    J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations.
    Jia Y; Akache B; Deschatelets L; Qian H; Dudani R; Harrison BA; Stark FC; Chandan V; Jamshidi MP; Krishnan L; McCluskie MJ
    Int J Pharm; 2019 Apr; 561():187-196. PubMed ID: 30836154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of rosuvastatin flexible lipid-based nanoparticles: promising nanocarriers for improving intestinal cells cytotoxicity.
    Ahmed TA
    BMC Pharmacol Toxicol; 2020 Feb; 21(1):14. PubMed ID: 32085802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.